These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17485597)

  • 1. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker.
    Skov K; Eiskjaer H; Hansen HE; Madsen JK; Kvist S; Mulvany MJ
    Hypertension; 2007 Jul; 50(1):89-95. PubMed ID: 17485597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of treating prehypertension with an angiotensin-receptor blocker.
    Julius S; Nesbitt SD; Egan BM; Weber MA; Michelson EL; Kaciroti N; Black HR; Grimm RH; Messerli FH; Oparil S; Schork MA;
    N Engl J Med; 2006 Apr; 354(16):1685-97. PubMed ID: 16537662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
    Sandset EC; Bath PM; Boysen G; Jatuzis D; Kõrv J; Lüders S; Murray GD; Richter PS; Roine RO; Terént A; Thijs V; Berge E;
    Lancet; 2011 Feb; 377(9767):741-50. PubMed ID: 21316752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
    Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
    Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
    Nakamura T; Kanno Y; Takenaka T; Suzuki H;
    Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal resistance and long-term blood pressure in individuals genetically predisposed for essential hypertension: 10-year follow-up of the Danish Hypertension Prevention Project.
    Buus NH; Mulvany MJ; Eiskjær H; Christensen KL; Skov K
    J Hypertens; 2016 Jun; 34(6):1170-7. PubMed ID: 27054529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
    Flesch M; Knipp S; Kessler G; Geissler HJ; Massoudy P; Wilhelm H; Philipp T; Erdmann E
    Clin Res Cardiol; 2009 Jan; 98(1):33-43. PubMed ID: 18853093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G; Schmieder R; Calvo C; Asmar R
    Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Chaturvedi N;
    Lancet; 2008 Oct; 372(9647):1385-93. PubMed ID: 18823658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
    Fliser D; Wagner KK; Loos A; Tsikas D; Haller H
    J Am Soc Nephrol; 2005 Apr; 16(4):1135-40. PubMed ID: 15716329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
    Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
    Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.